Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
LY4005130 antibody treatment for nonsegmental vitiligo
Official title: A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Status: Recruiting now
Description:
Eli Lilly and Company plans to enroll about 66 participants. LY4005130 is an experimental antibody that neutralizes XCL1 and XCL2 signals linked to harmful CD8 T cells. It is designed to reduce the immune attack on melanocytes and encourage repigmentation. Possible risks include infusion reactions, headache, and infections; its full safety profile is not yet known. People ages 18 to 75 may qualify. The study is recruiting at 35 listed sites across 5 countries.
Start date: April 14, 2026
Completion date: September 01, 2027
Organizer: Eli Lilly and Company
Contact: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Tel.: 1-317-615-4559
Email: LillyTrials@Lilly.com
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Which is better for judging vitiligo — Wood’s lamp or dermoscopy?
A recent study out of India compared the two head-to-head. Both tools correlated fairly well with clinical criteria, but dermoscopy had a slight edge: Wood’s lamp: sensitivity 7...
- Vitiligo trials for kids: basics for the parents
Pediatric vitiligo trials · The basics Two parallel studies are evaluating investigational use of ruxolitinib cream in young children — researchers are still finding out how wel...
- Which diseases most commonly accompany vitiligo?
Vitiligo is rarely an isolated event. Because it involves an overactive immune system, it often coexists with other autoimmune disorders. According to extensive 10-year clinical...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.